ABVC BioPharma (ABVC) vs Atossa Therapeutics (ATOS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ABVC BioPharma (ABVC) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 69.8% versus a loss of 85.5%. Over five years, ATOS leads with a -94.4% price change compared with -96.4% for ABVC. ABVC BioPharma is the larger company by market cap ($26.7 million vs $24.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | ATOS |
|---|---|---|
| Share price | $1.00 | $2.44 |
| Market cap | $26.69M | $24.35M |
| 1-day change | +2.04% | +0.83% |
| YTD return | -53.99% | -72.66% |
| 1-year return | -69.75% | -85.47% |
| 5-year return | -96.38% | -94.36% |
| EPS (TTM) | $-0.30 | $-4.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.33 | $18.00 |
| 52-week low | $0.707 | $1.70 |
| Distance from 52-week high | -69.93% | -86.44% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +678.69% |
| Average volume | 111.36K | 63.48K |
| Shares outstanding | 26.69M | 9.98M |
| Employees | 16 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABVC has outperformed ATOS by 15.7 percentage points over the past year.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
ABVC vs ATOS FAQ
Which is bigger, ABVC BioPharma or Atossa Therapeutics?
ABVC BioPharma (ABVC) is larger, with a market capitalization of $26.69M compared with $24.35M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, ABVC or ATOS?
ABVC returned -69.75% over the past 12 months, compared with -85.47% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and Atossa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.